CD19/CD22 bicistronic CAR T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19/CD22 bicistronic CAR T cells, covering 2026-03-12 to 2026-03-12. Get the full timeline:
Most recent: Clinical Trial Update: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies [Phase 1, Phase 2]